Who
Andrew N. Schiff
Director
Company insider
Files Form 4 as: Director, Monte Rosa Therapeutics; Director, Aclaris Therapeutics; 10% owner and Other, Elevation Oncology; 10% owner, Loxo Oncology; Director and 10% owner, Zeltiq Aesthetics; Director and 10% owner, Agile Therapeutics; 10% owner, T2 Biosystems; Director and 10% owner, Transenterix.
In numbers
- Trades disclosed
- 110
- Buys
- 5
- Sells
- 23
- Bought
- $23.2M
- Sold
- $291.8M
- Companies
- 11
- Companies where not an officer
- 11
- First trade
- 14 Jun 2012
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 6 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,793 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,793 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,580 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,750 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,793 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,660 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,660 | filing |
News
Arcturus Therapeutics (NASDAQ:ARCT) & ADMA Biologics (NASDAQ:ADMA) Head-To-Head SurveyADMA · dailypolitical.com · 18 Oct 2026Analyzing Anika Therapeutics (NASDAQ:ANIK) & ADMA Biologics (NASDAQ:ADMA)ADMA · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Andrew N. Schiff; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.